Ablavar (previously Vasovist)
gadofosveset trisodium
Table of contents
Overview
The marketing authorisation for Ablavar has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Ablavar (previously Vasovist)
|
| Agency product number |
EMEA/H/C/000601
|
| Active substance |
gadofosveset trisodium
|
| International non-proprietary name (INN) or common name |
gadofosveset trisodium
|
| Therapeutic area (MeSH) |
Magnetic Resonance Angiography
|
| Anatomical therapeutic chemical (ATC) code |
V08CA
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
TMC Pharma Services Ltd.
|
| Revision |
10
|
| Date of issue of marketing authorisation valid throughout the European Union |
03/10/2005
|
| Contact address |
Finchampstead
Berkshire RG40 4LJ United Kingdom |
Product information
15/05/2011 Ablavar (previously Vasovist) - EMEA/H/C/000601 - IB/0020
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Contrast media
Therapeutic indication
This medicinal product is for diagnostic use only.
Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease.